The research team began by characterizing what aging actually does to the body before any infection takes place. They compared young C57BL/6 mice, aged eight to twelve weeks, with old mice aged twenty-four months. Microscopic examination of lung tissue revealed disrupted cytoskeletal architecture in the old animals, a sign of structural deterioration. Blood analysis showed pronounced systemic inflammation, with significantly elevated levels of interferons, the pro-inflammatory cytokines IL-6 and IL-1β, and chemokines such as IL-8, MCP-1, and CXCL-1. The anti-inflammatory cytokine IL-10, itself a factor secreted by senescent cells, was also elevated. Transcriptomic profiling of lung tissue confirmed the picture, revealing enrichment of inflammation-related pathways including phagosome activity, antigen presentation, and cytokine-cytokine receptor interactions, all pointing to heightened immune activation in the aged lung even in the absence of any pathogen.

The gut told a parallel story. Shotgun metagenomic sequencing of fecal samples showed marked age-associated shifts in microbial composition, with an increased abundance of the genus Clostridium and a significant depletion of Faecalibaculum in the old mice. An analysis of similarities confirmed that the microbial communities of old and young mice differed significantly at the genus level. Taken together, these baseline findings established a coordinated profile of aging: systemic cytokine elevation, inflammatory transcriptional changes in the lung, and gut dysbiosis, providing the foundation for asking how these changes shape the response to viral infection.

When the researchers infected both age groups with a sublethal dose of influenza A virus, distinct age-dependent patterns emerged. Young mice mounted an early, transient response, showing higher clinical scores during the first days of infection but recovering fully by the end of the observation period. Old mice followed a different trajectory: their clinical deterioration appeared later, from day eight onward, and their body weight never fully returned to baseline by day twenty-one. Critically, the bronchoalveolar lavage fluid of old mice contained higher viral loads on day eight, along with elevated levels of IL-6, IP-10, and IFN-γ. In other words, the aged animals cleared the virus more slowly while simultaneously producing more inflammatory signaling molecules.

Transcriptomic analysis of lung tissue mirrored this delayed but exaggerated response. On day four post-infection, infected old mice showed relatively subdued inflammatory gene expression compared with infected young mice, including significantly decreased expression of several type I and type III interferons such as Ifnl2, Ifna4, and Ifnl3. By day eight, however, the old mice displayed a significant surge in inflammation-related genes, with the notable exception of the interferons, alongside enrichment of pattern recognition receptor pathways such as Toll-like receptor cascades. This pattern suggests that aging disrupts the coordination between early antiviral immunity and the later resolution of inflammation, allowing both the virus and the inflammatory response to persist longer.

The most novel part of the study concerned what was happening in the gut during infection. Shotgun metagenomics of samples taken at baseline, day four, and day twenty-one post-infection revealed that influenza infection transiently reshaped the microbiome in both age groups, with decreases in Bacillota and increases in Verrucomicrobiota and Pseudomonadota during the acute phase. Akkermansia increased in both groups, most prominently in old mice, while species-level analysis showed that the two most abundant species, Faecalibaculum rodentium and Akkermansia muciniphila, were significantly decreased in old mice even before infection and remained lower throughout. Linear discriminant analysis highlighted strong effect sizes for these beneficial species in young mice, and for Escherichia coli and Parabacteroides goldsteinii in old mice during the acute phase.

More revealing than the taxonomic shifts were the changes in metabolic potential. Genes annotated to the CAZy database showed that enzymes involved in glucose fermentation were transiently upregulated in both age groups during acute infection, with the effect particularly pronounced in old mice, consistent with the central role of carbohydrate fermentation in short-chain fatty acid production. However, KEGG-based functional annotation indicated a potential decline in pyruvate production via the Entner-Doudoroff pathway and, crucially, reduced acetate generation through pyruvate dehydrogenase (quinone) in the old animals. Because acetate is a major microbiota-derived metabolite with established immunomodulatory and antiviral properties, this age-related decline in acetate-associated metabolism suggested a concrete mechanistic link between gut dysfunction and impaired antiviral defense.

To test that link directly, the team turned to a human cell model. They induced senescence in primary human lung fibroblasts (IMR-90 cells) using doxorubicin, confirming the senescent state through upregulation of p21, downregulation of Lamin B1, and elevated senescence-associated secretory phenotype markers. Flow cytometry revealed that senescent cells significantly overexpressed FFAR2 and FFAR3, the G-protein-coupled receptors that mediate short-chain fatty acid signaling. Consistent with the group’s previous work, senescent fibroblasts proved markedly more permissive to influenza A virus than quiescent controls, replicating the virus to much higher levels. But when the cells were pre-treated with 260 micromolar acetate for twenty-four hours before infection, viral replication dropped significantly, and inflammatory cytokine output was dampened, all without compromising cell viability. Acetate, in effect, restored a measure of antiviral defense to the aged cells.

The mechanism appears to be both immunological and epigenetic. RNA sequencing showed that influenza-infected senescent cells upregulate numerous inflammation and pathogen recognition pathways, including NF-κB and NOD-like receptor signaling, whereas these pathways remained largely unchanged when acetate was present. Ingenuity Pathway Analysis confirmed that pathogen-induced cytokine storm signaling was strongly elevated in infected senescent cells but attenuated by acetate treatment, while pathways linked to cellular senescence itself were unaffected. Acetate also enhanced pathways related to oxidative phosphorylation and reactive oxygen species production, suggesting it pushes cells toward a metabolic state less permissive to viral replication. The enzyme ACSS2, which activates acetate for histone modification, was upregulated in senescent fibroblasts, and histone extracts revealed that influenza infection decreased H3 acetylation in senescent cells, a reduction that acetate supplementation restored. Histone deacetylase activity, reduced at baseline in senescent cells, was likewise normalized by acetate. This coordinated epigenetic remodeling likely underlies the broad transcriptional changes that suppress both viral replication and cytokine overproduction.

The authors are careful to note the limits of the current work. Direct quantification of short-chain fatty acids, metabolomic profiling of primary old human lung tissue, and validation in clinical cohorts will be needed to establish a firm causal relationship between microbiota-derived metabolites and antiviral resilience in aging humans, and to determine whether circulating acetate levels correlate with influenza severity in older patients. Even so, the study delivers a compelling translational framework: age-associated gut dysbiosis reduces the microbial capacity to produce acetate, and this decline in metabolite availability directly compromises antiviral responses in senescent lung cells through FFAR2/FFAR3 signaling and histone acetylation. Because individuals over sixty experience substantially higher morbidity, mortality, and prolonged hospitalization from influenza, the identification of a modifiable, microbiota-derived mediator opens a concrete therapeutic avenue. Host-directed interventions that boost acetate availability, whether through diet, probiotics, or targeted metabolite supplementation, could one day help restore antiviral resilience in the aging lung, complementing vaccines rather than replacing them.

Subject of Research: Age-associated gut microbiota dysbiosis, short-chain fatty acid metabolism, and impaired antiviral defense during influenza infection

Article Title: Age‐Associated Gut Microbiota Dysbiosis Impairs Antiviral Defense During Influenza Virus Infection and Identifies Acetate as a Protective Mediator in Senescent Human Lung Cells

Article References: Wernike, C., Häder, A., Reisser, Y., Garakani, K., Hornung, F., Le Saux, C. J., & Deinhardt‐Emmer, S. (2026). Age‐Associated Gut Microbiota Dysbiosis Impairs Antiviral Defense During Influenza Virus Infection and Identifies Acetate as a Protective Mediator in Senescent Human Lung Cells. Aging Cell, 25(10), Article e70750. https://doi.org/10.1111/acel.70750

Image Credits: AI Generated

DOI: 10.1111/acel.70750

Keywords: gut microbiota, aging, influenza A virus, acetate, short-chain fatty acids, gut-lung axis, cellular senescence, FFAR2, histone acetylation, antiviral immunity, dysbiosis, lung fibroblasts

The starting point for the investigation was a careful characterization of what actually goes wrong in diarrheic calves. Compared with healthy animals, calves suffering from neonatal diarrhea showed pronounced gut microbial dysbiosis, meaning the composition of their intestinal bacterial communities had shifted away from a balanced state, together with measurable metabolic perturbation and clear signs of inflammatory activation. These observations established the pathological backdrop against which any candidate intervention would need to be evaluated, and they highlighted the possibility that restoring a healthy microbial community might restore a healthy gut.

To test that possibility directly, the researchers turned to fecal microbiota transplantation, or FMT, a technique that transfers the entire gut microbial community from healthy donor animals into sick recipients. When fecal material from healthy calves was transplanted into diarrheic calves, the treatment alleviated diarrhea. Crucially, the recovery was accompanied by enrichment of B. pseudocatenulatum in the recipients’ intestines and by an increase in fecal acetate, one of the major short-chain fatty acids produced by bacterial fermentation in the gut. This correlation gave the team two concrete leads: a specific bacterial species and a specific bacterial metabolite that moved in the same direction as clinical improvement.

The next step was to determine whether the bacterium itself could generate the acetate signal. In laboratory cultures, live B. pseudocatenulatum increased acetate production, confirming that this species is a genuine acetate producer rather than a passive correlate of health. This matters because it establishes a plausible causal route from bacterium to metabolite to host physiology, rather than a mere association, and it focused the team’s attention on acetate as the likely functional mediator of the probiotic effect.

To dissect that mechanism under controlled conditions, the investigators used complementary murine inflammatory models, in which mice were subjected to inflammatory challenges that mimic the intestinal damage seen in diarrheic calves. Treatment with live B. pseudocatenulatum or with acetate itself alleviated intestinal injury and the associated inflammatory phenotypes in these animals. By contrast, the protective effect was attenuated in mice given heat-killed B. pseudocatenulatum, a result with important mechanistic implications: a dead bacterium cannot ferment substrates into metabolites, so the loss of protection when the organism is killed points squarely to an activity of living bacteria, most plausibly their metabolic output, as the source of the benefit rather than a structural component of the bacterial cell.

Perhaps the most technically interesting part of the study concerns the immune pathway that the bacterium and its metabolite engage. The team found that the protective effects were accompanied by attenuation of pathogen-induced Th17/IL-17A-related responses. The Th17 lineage is a subset of CD4-positive T helper cells defined in large part by their production of the cytokine interleukin-17A, a potent inflammatory messenger that recruits neutrophils and drives antimicrobial defense but also fuels tissue damage when overactivated. Importantly, the authors emphasize that the effect was not a broad suppression of basal Th17 activation; the bacterium and acetate selectively dampened the exaggerated, pathogen-driven arm of this response while leaving ordinary Th17 activity largely intact. That selectivity is a desirable property for any anti-inflammatory therapy, because wholesale immune suppression would leave young animals vulnerable to infection.

The team then probed the receptor side of the acetate signal. Acetate can signal to host cells through free fatty acid receptor 2, or FFAR2, a G-protein-coupled receptor expressed on immune and epithelial cells that functions as a sensor for short-chain fatty acids. When the researchers used pharmacological blockade of FFAR2, the protective effect of live B. pseudocatenulatum was attenuated, supporting the involvement of acetate-associated receptor signaling in the probiotic benefit. Complementary experiments reported in the supplementary material of the study also showed that Brodalumab, an antibody that blocks the signaling of IL-17 family cytokines, counteracted the protective effect of acetate in a mouse colitis model driven by Salmonella Typhimurium, further tying the pathway together at the cytokine level.

The murine models tested a range of inflammatory insults beyond a single pathogen, and the results were consistent across them. B. pseudocatenulatum and acetate, supplied as sodium acetate, protected against intestinal injury in mice challenged with Escherichia coli and in models of Salmonella Typhimurium-induced inflammation and DSS-induced colonic inflammation. In the E. coli-challenged mice, the bacterium restored intestinal morphology, promoted acetate production, remodeled gut microbiota composition, and modulated T-cell subsets and inflammatory factors, along with the expression of genes involved in immune responses and metabolism in the intestinal epithelium. Supplementary analyses in calves showed that sodium acetate supplementation influenced serum biochemical indicators, extending the metabolite-level evidence to the target species itself.

Taken together, the study lays out a coherent mechanistic framework: dysbiosis in diarrheic calves depletes protective, acetate-producing taxa such as B. pseudocatenulatum; restoring those taxa, whether by whole-community FMT or by targeted supplementation, replenishes the acetate pool; acetate then acts through FFAR2 to restrain the pathogen-induced surge of the Th17/IL-17A axis, thereby reducing intestinal inflammation and the diarrhea it produces. The authors present this as one component of the bacterium’s protective effect rather than the whole story, a measured framing that reflects the inherent complexity of gut ecosystems and the many metabolites and immune circuits that operate in parallel.

The practical implications are considerable. Neonatal calf diarrhea imposes substantial economic losses on dairy and beef operations worldwide, and current management relies heavily on antibiotics, rehydration therapy, and husbandry measures, approaches that face growing pressure from antimicrobial resistance concerns. A defined probiotic species with an understood mechanism of action, acting through a well-characterized metabolite and receptor pathway, offers a rational and mechanistically grounded alternative or complement to existing treatments. More broadly, the microbiota–metabolite–immune regulatory framework established in this work provides a template that researchers in animal science and human gastroenterology alike can use to dissect how specific commensal organisms and their metabolic products tune inflammatory responses, and it underscores how much therapeutic insight can be extracted from tracing a single bacterial species and its small-molecule signal from the feces of a sick calf all the way to a cytokine axis in the gut wall.

Subject of Research: Acetate-mediated immune modulation by Bifidobacterium pseudocatenulatum in neonatal calf diarrhea

Article Title: Bifidobacterium pseudocatenulatum alleviates neonatal calf diarrhea via acetate-associated attenuation of pathogen-induced Th17/IL-17A inflammatory responses

Article References: Hu, M., Du, W., Li, W., Du, Y., Si, W., Hou, J., Gao, Y., Yang, L., Sun, H., Liu, H., Yu, Z., Guan, L., & Xu, Q. (2026). Bifidobacterium pseudocatenulatum alleviates neonatal calf diarrhea via acetate-associated attenuation of pathogen-induced Th17/IL-17A inflammatory responses. Microbiome. https://doi.org/10.1186/s40168-026-02524-4

Image Credits: AI Generated

DOI: 10.1186/s40168-026-02524-4

Keywords: Bifidobacterium pseudocatenulatum, neonatal calf diarrhea, gut microbiome, acetate, short-chain fatty acids, Th17 cells, IL-17A, FFAR2, intestinal inflammation, fecal microbiota transplantation, probiotics, livestock health